# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-197577
Filing Date
2026-04-30
Accepted
2026-04-30 16:38:19
Documents
3
Period of Report
2026-06-17

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | mink-def_14a_2026.htm | DEF 14A | 688842
2 | GRAPHIC | img69721585_0.jpg | GRAPHIC | 333665
3 | GRAPHIC | img69721585_1.jpg | GRAPHIC | 361762
| Complete submission text file | 0001193125-26-197577.txt |  | 1648008

Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40908 | Film No.: 26926372
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)